Medivir AB has partnered with Biossil Inc. to develop remetinostat, a drug applied to the skin that is currently in phase 2 of clinical trials. Biossil will have the rights to develop and sell remetinostat worldwide. This drug has shown promising results in treating certain skin cancers. If the drug is successful and approved, Medivir could earn up to $60 million and a percentage of future sales. Jens Lindberg, CEO of Medivir, stated that this agreement aligns with their goal to create and market new cancer treatments. He expressed enthusiasm for Biossil’s work on remetinostat. Biossil, a Toronto-based company, uses AI to develop drugs for diseases with significant unmet medical needs. They plan to continue developing remetinostat using their unique methods. Dr. Alexander Mosa, a key figure at Biossil, highlighted that remetinostat was chosen for its promising trial data and potential to meet important medical needs. He also expressed gratitude for Medivir’s support. This partnership is a significant move for both companies in their quest to develop innovative cancer treatments.